NCT05881564

Brief Summary

To evaluate if there is any clinical difference in patients 3.5-12kg who undergo cardiac surgery with cardiopulmonary bypass that do and do not receive blood products as part of their procedure. The main hypothesis of the study is that the patients undergoing bloodless cardiac surgery will have decreased morbidity and mortality when compared to the cohort that did receive blood as well as a shorter ICU and hospital length of stay.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 10, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

May 10, 2023

Completed
21 days until next milestone

First Posted

Study publicly available on registry

May 31, 2023

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 11, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

May 12, 2026

Completed
Last Updated

June 1, 2023

Status Verified

May 1, 2023

Enrollment Period

2 years

First QC Date

May 10, 2023

Last Update Submit

May 30, 2023

Conditions

Outcome Measures

Primary Outcomes (21)

  • Age of patients undergoing bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    age in months

    30 days

  • Weight of patients undergoing bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    weight in kg

    30 days

  • Gender of patients undergoing bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    sex

    30 days

  • Demographics of bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    race

    30 days

  • Diagnosis of patients undergoing bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    preoperative diagnosis

    30 days

  • Surgery performed in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    surgery performed

    30 days

  • Previous surgery prior to bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    any previous surgery

    30 days

  • Blood received during bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    blood product received

    30 days

  • Volume transfused during bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    volume of blood transfusion in mL

    30 days

  • Number of patients with unplanned reoperation in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    unplanned reoperation

    30 days

  • Number of patients with unplanned cardiac catheterization in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    unplanned cardiac catheterization

    30 days

  • Number of patients with a neurologic complication in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    neurologic complication

    30 days

  • Number of patients with chylothorax in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    chylothorax

    30 days

  • Number of patients with vocal cord injury in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    vocal cord injury

    30 days

  • Number of patients with diaphragm paralysis in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    diaphragm paralysis

    30 days

  • Number of patients with pacemaker implantation in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    pacemaker implantation

    30 days

  • Number of patients with postoperative pneumothorax in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    postoperative pneumothorax

    30 days

  • Number of patients with wound infection in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    wound infection

    30 days

  • Number of patients with bleeding requiring reoperation in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    bleeding requiring reoperation

    30 days

  • Number of patients with pericardial effusion in bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    pericardial effusion

    30 days

  • Number of patients who died following bloodless cardiac surgery in patients 3.5-12kg (categorical variable)

    mortality

    30 days

Study Arms (2)

Blood prime for cardiopulmonary bypass

ACTIVE COMPARATOR
Other: blood use for priming cardiopulmonary bypass circuit

clear prime for cardiopulmonary bypass

ACTIVE COMPARATOR
Other: clear prime for cardiopulmonary bypass

Interventions

one arm will have the cardiopulmonary bypass circuit primed with blood

Blood prime for cardiopulmonary bypass

this arm will not have bypass circuit primed with blood

clear prime for cardiopulmonary bypass

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patient weight 3.5-12kg
  • Elective and urgent cardiac surgery with cardiopulmonary bypass
  • Cases within the STS STAT categories of 1-4

You may not qualify if:

  • Patients who weigh more than 12kg or less than 3.5kg.
  • Patients undergoing emergency surgery.
  • STAT category 5 cases.
  • Patients whose surgery does not require cardiopulmonary bypass.
  • Patients presenting preoperatively in shock.
  • Patients with known blood dyscrasias.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Hospital of Georgia

Augusta, Georgia, 30912, United States

RECRUITING

MeSH Terms

Conditions

Heart Defects, Congenital

Interventions

Cardiopulmonary Bypass

Condition Hierarchy (Ancestors)

Cardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Extracorporeal CirculationSurgical Procedures, Operative

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 10, 2023

First Posted

May 31, 2023

Study Start

May 10, 2023

Primary Completion

May 11, 2025

Study Completion

May 12, 2026

Last Updated

June 1, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will not share

Locations